Tumor Suppressor Proteins
"Tumor Suppressor Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
| Descriptor ID |
D025521
|
| MeSH Number(s) |
D12.776.624.776
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Proteins".
Below are MeSH descriptors whose meaning is more specific than "Tumor Suppressor Proteins".
This graph shows the total number of publications written about "Tumor Suppressor Proteins" by people in this website by year, and whether "Tumor Suppressor Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 3 | 4 |
| 2000 | 5 | 2 | 7 |
| 2001 | 4 | 3 | 7 |
| 2002 | 3 | 3 | 6 |
| 2003 | 2 | 6 | 8 |
| 2004 | 5 | 4 | 9 |
| 2005 | 4 | 7 | 11 |
| 2006 | 4 | 1 | 5 |
| 2007 | 5 | 3 | 8 |
| 2008 | 8 | 6 | 14 |
| 2009 | 4 | 5 | 9 |
| 2010 | 6 | 8 | 14 |
| 2011 | 8 | 3 | 11 |
| 2012 | 11 | 3 | 14 |
| 2013 | 9 | 11 | 20 |
| 2014 | 8 | 5 | 13 |
| 2015 | 3 | 6 | 9 |
| 2016 | 6 | 6 | 12 |
| 2017 | 3 | 3 | 6 |
| 2018 | 2 | 4 | 6 |
| 2019 | 3 | 3 | 6 |
| 2020 | 5 | 2 | 7 |
| 2021 | 4 | 5 | 9 |
| 2022 | 2 | 5 | 7 |
| 2023 | 1 | 3 | 4 |
| 2024 | 1 | 3 | 4 |
| 2025 | 6 | 1 | 7 |
| 2026 | 1 | 5 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Suppressor Proteins" by people in Profiles.
-
Tumor-targeted interferon-a gene therapy for glioblastoma: a phase 1 trial. Nat Med. 2026 Jun; 32(6):2216-2226.
-
Association of genomic driver mutation, histologic subtype, and mTORC1 biomarker expression in mTOR pathway-altered renal tumors. Hum Pathol. 2026 Sep; 175:106154.
-
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and Programmed Death-Ligand 1 Expression on Overall Survival in a Select Cohort From the International Association for the Study of Lung Cancer Ninth Edition Staging Database. J Thorac Oncol. 2026 Jul; 21(7):103681.
-
The impact of next generation sequencing studies on the diagnosis of BAP1 inactivated melanocytic tumors. Hum Pathol. 2026 Jun; 172:106103.
-
aPKC and F-actin dynamics promote Hippo pathway polarity in asymmetrically dividing neuroblasts. Biol Open. 2026 Mar 15; 15(3).
-
p63-Positive Diffuse Large B-cell Lymphoma of Oropharynx: A Treacherous Mimic of HPV-Related Squamous Cell Carcinoma-A Report of Three Cases. Head Neck Pathol. 2026 Jan 23; 20(1):15.
-
Identification of targetable epigenetic vulnerabilities for uveal melanoma. Cell Death Dis. 2025 Dec 12; 17(1):89.
-
Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. J Clin Oncol. 2025 09 20; 43(27):3032-3040.
-
The role of extent of resection, chemoradiation, and MGMT promoter methylation in overall survival in a large cohort of IDH-wildtype glioblastoma. Neurosurg Focus. 2025 08 01; 59(2):E9.
-
Clinical and Pathologic Phenotyping of Mesotheliomas Developing in Carriers of Germline BAP1 Mutations. J Thorac Oncol. 2025 11; 20(11):1683-1698.